Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Eisai
Company Monitoring Page for Eisai
latest headlines for company on cafepharma
Lilly powers through final stretch in critical Alzheimer's race
Fierce Biotech
Tue, 11/1/22 - 07:02 pm
Tags:
Eli Lilly
,
Alzheimer's disease
,
donanemab
,
lecanemab
,
Eisai
Eisai's Alzheimer's hopeful lecanemab may have contributed to patient death: report
Fierce Biotech
Mon, 10/31/22 - 10:30 am
Tags:
Eisai
,
patient death
,
lecanemab
,
Alzheimer's disease
,
clinical trials
Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success
Bloomberg
Wed, 10/19/22 - 10:35 am
Tags:
Roche
,
Pharma CEOs
,
Severin Schwan
,
Alzheimer's disease
,
Eisai
,
gantenerumab
,
lecanemab
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
Wed, 10/12/22 - 11:03 am
Tags:
FDA
,
Biogen
,
Eisai
,
Alzheimer's disease
,
Gilead Sciences
,
HIV
,
Mirati Therapeutics
,
lung cancer
,
lecanemab
,
lenacapavir
,
adagrasib
Eisai cuts the ribbon on $69M injectable drug delivery facility
Fierce Pharma
Tue, 10/11/22 - 10:26 am
Tags:
Eisai
,
injectables
,
drug delivery
,
R&D
The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
Tags:
biopharma stocks
,
AbbVie
,
Alnylam
,
AstraZeneca
,
Biogen
,
CRISPR Therapeutics
,
Daiichi Sankyo
,
Eisai
,
Eli Lilly
,
GSK
,
Intellia Therapeutics
,
Regeneron
,
Roche
,
Sanofi
,
Sarepta Therapeutics
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Tags:
Biogen
,
Eisai
,
Alzheimer's disease
,
Arrowhead Pharmaceuticals
,
Takeda
,
RNAi
,
Madrigal
,
NASH
,
Ascendis
,
FDA
Lecanemab can; now the wait for details begins
EP Vantage
Wed, 09/28/22 - 11:45 am
Tags:
Biogen
,
Eisai
,
lecanemab
,
clinical trials
,
Alzheimer's disease
Biogen/Eisai Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
Stat
Wed, 09/28/22 - 12:04 am
Tags:
Biogen
,
Eisai
,
Alzheimer's disease
,
clinical trials
,
lecanemab
Eisai inaugurates new US HQ as closely watched FDA Alzheimer's decision draws near
Fierce Pharma
Sun, 08/21/22 - 09:36 pm
Tags:
Eisai
,
headquarters
,
Alzheimer's disease
,
FDA
July Brings Layoffs, Job Creation for the Life Sciences
BioSpace
Wed, 08/3/22 - 09:32 pm
Tags:
layoffs
,
hirings
,
Astellas
,
Pfizer
,
Eikon Therapeutics
,
Bayer
,
Avadel Pharma
,
Heron Therapeutics
,
Adverum Biotechnologies
,
Biogen
,
Eisai
,
X4 Pharmaceuticals
,
Assembly Biosciences
Eisai closing oncology R&D wing H3 Biomedicine for good
Fierce Biotech
Mon, 07/18/22 - 07:23 pm
Tags:
Eisai
,
oncology
,
H3 Biomedicine
,
layoffs
,
R&D
Biogen-Eisai go for another biomarker approval in Alzheimer's with lecanemab—and snag priority review
Fierce Biotech
Tue, 07/5/22 - 11:58 pm
Tags:
Biogen
,
Eisai
,
FDA
,
biomarkers
,
Alzheimer's disease
,
lecanemab
ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC
Pharmaforum
Mon, 06/6/22 - 11:52 pm
Tags:
ASCO 2022
,
Eisai
,
antibody-drug conjugate
,
Bristol Myers Squibb
,
MORAb-202
Simulation model shows potential clinical value of Eisai drug for patients with early AD
Biopharma Reporter
Mon, 05/9/22 - 10:15 am
Tags:
Eisai
,
Alzheimer's disease
,
lecanemab
Biogen shoves Aduhelm to the side. It's time for lecanemab
Fierce Biotech
Wed, 05/4/22 - 10:33 am
Tags:
Biogen
,
Aduhelm
,
lecanemab
,
Eisai
,
Alzheimer's disease
Biogen, Eisai unveil new data on lecanemab, but questions linger on ARIA-E; Spatial biology outfit grabs $33M round
Endpoints
Tue, 03/22/22 - 11:19 pm
Tags:
Eisai
,
Biogen
,
lecanemab
,
Alzheimer's disease
Eisai hands off responsibility for Aduhelm to Biogen
Pharmaforum
Tue, 03/15/22 - 11:43 am
Tags:
Eisai
,
Biogen
,
Aduhelm
,
Alzheimer's disease
Roivant decants another Vant armed with Eisai blood cancer drug and plans to start phase 1/2 soon
Fierce Biotech
Mon, 02/14/22 - 12:05 pm
Tags:
Hemavant
,
Roivant Sciences
,
Eisai
,
MDS
,
RVT-2001
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Tags:
Eisai
,
Biogen
,
Aduhelm
,
Alzheimer's disease
,
FDA
,
CMS
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.